1-ethyl-piperidine-3-carboxylic acid diethylamide | 3367-94-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-ethyl-piperidine-3-carboxylic acid diethylamide
• 英文别名: 1-Aethyl-piperidin-3-carbonsaeure-diaethylamid；1-Ethyl-piperidin-3-(N,N-diethylcarboxamid)；N,N,N'-Triethylnipecotamide；N,N,1-triethylpiperidine-3-carboxamide
• CAS: 3367-94-0
• 化学式: C₁₂H₂₄N₂O
• 分子量: 212.335
• InChiKey: OIYHTABGPWSCIY-UHFFFAOYSA-N

物化性质

• 沸点：
  312.0±31.0 °C(Predicted)
• 密度：
  0.951±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  溴乙烷 、 尼可刹米 在 苯 作用下， 生成 1-ethyl-piperidine-3-carboxylic acid diethylamide
  参考文献：
  名称：

  Notes - 3-(N,N-Dialkylcarboxamido)piperidinoalkanes

  摘要：

  DOI：

  10.1021/jo01358a611

文献信息

• Crf Receptor Antagonists and Methods
  申请人：Luo Zhiyong

  公开号：US20070293511A1

  公开（公告）日：2007-12-20

  CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , Y, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

  本发明揭示了具有治疗多种疾病的用途的CRF受体拮抗剂，包括治疗在恒温动物中表现为CRF过度分泌的疾病，如中风。本发明的CRF受体拮抗剂具有以下结构：包括立体异构体、前药和药学上可接受的盐，其中R1、R2、R3、Y、Ar和Het的定义如本文所述。还揭示了含有CRF受体拮抗剂和药学上可接受的载体的组合物，以及使用它们的方法。
• [EN] COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN<br/>[FR] COMPOSÉS UTILES COMME INHIBITEURS DE LA PROTÉINE HÉLIOS
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2021101919A1

  公开（公告）日：2021-05-27

  Disclosed are compounds of Formula (I) or a salt thereof, wherein Z is CR6R6 or C=O; Ring A is, and R1, R2, R3, R4, R5, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.